Page 421 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 21 Mast Cell Tumors 399

72. Fox LE, Rosenthal RC, Twedt DC, et al.: Plasma histamine and 93. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al.: Cellular pro-
gastrin concentrations in 17 dogs with mast cell tumors, J Vet Intern liferation in canine cutaneous mast cell tumors: associations with
Med 4:242–246, 1990. c-KIT and its role in prognostication, Vet Pathol 44:298–308, 2007.
VetBooks.ir 73. Howard EB, Sawa TR, Nielsen SW, et al.: Mastocytoma and gas- 94. Maglennon GA, Murphy S, Adams V, et al.: Association of Ki67
index with prognosis for intermediate-grade canine cutaneous mast
troduodenal ulceration. Gastric and duodenal ulcers in dogs with
cell tumours, Vet Comp Oncol 6:268–274, 2008.
mastocytoma, Pathol Vet 6:146–158, 1969.
74. Ishiguro T, Kadosawa T, Takagi S, et al.: Relationship of disease 95. Ozaki K, Yamagami T, Nomura K, et al.: Prognostic significance of
progression and plasma histamine concentrations in 11 dogs with surgical margin, Ki-67 and cyclin D1 protein expression in grade
mast cell tumors, J Vet Intern Med 17:194–198, 2003. II canine cutaneous mast cell tumor, J Vet Med Sci 69:1117–1121,
75. Roberts II LJ, Sweetman BJ, Lewis RA, et al.: Increased production 2007.
of prostaglandin D2 in patients with systemic mastocytosis, N Engl 96. Sakai H, Noda A, Shirai N, et al.: Proliferative activity of canine
J Med 303:1400–1484, 1980. mast cell tumours evaluated by bromodeoxyuridine incorporation
76. Scott HW, Parris WCV, Sandidge PC, et al.: Hazards in opera- and Ki-67 expression, J Comp Pathol 127:233–238, 2002.
tive management of patients with systemic mastocytosis, Ann Surg 97. Thompson JJ, Yager JA, Best SJ, et al.: Canine subcutaneous mast
197:507–514, 1983. cell tumors: cellular proliferation and KIT expression as prognostic
77. Hottendorf GH, Nielsen SW, Kenyon AJ: Canine mastocytoma: indices, Vet Pathol 48:169–181, 2011.
I. Blood coagulation time in dogs with mastocytoma, Pathol Vet 98. Bostock DE, Crocker J, Harris K, et al.: Nucleolar organiser regions
2:129–141, 1965. as indicators of post-surgical prognosis in canine spontaneous mast
78. Murphy S, Sparkes AH, Smith KC, et al.: Relationships between the cell tumours, Br J Cancer 59:915–918, 1989.
histological grade of cutaneous mast cell tumours in dogs, their survival 99. Kravis LD, Vail DM, Kisseberth WC, et al.: Frequency of argyr-
and the efficacy of surgical resection, Vet Rec 154:743–746, 2004. ophilic nucleolar organizer regions in fine-needle aspirates and
79. Simoes JP, Schoning P, Butine M: Prognosis of canine mast cell biopsy specimens from mast cell tumors in dogs, J Am Vet Med
tumors: a comparison of three methods, Vet Pathol 31:637–647, Assoc 209:1418–1420, 1996.
1994. 100. Romansik EM, Reilly CM, Kass PH, et al.: Mitotic index is predic-
80. Michels GM, Knapp DW, DeNicola DB, et al.: Prognosis following tive for survival for canine cutaneous mast cell tumors, Vet Pathol
surgical excision of canine cutaneous mast cell tumors with histo- 44:335–341, 2007.
pathologically tumor-free versus nontumor-free margins: a retrospec- 101. Elston L, Sueiro FA, Cavalcanti J, et al.: The importance of the
tive study of 31 cases, J Am Anim Hosp Assoc 38:458–466, 2002. mitotic index as a prognostic factor for canine cutaneous mast cell
81. Seguin B, Leibman NF, Bregazzi VS, et al.: Clinical outcome of tumors - a validation study, Vet Pathol 46:362–365, 2009.
dogs with grade-II mast cell tumors treated with surgery alone: 55 102. Preziosi R, Sarli G, Paltrinieri M: Multivariate survival analysis of
cases (1996-1999), J Am Vet Med Assoc 218:1120–1123, 2001. histological parameters and clinical presentation in canine cutane-
82. Weisse C, Shofer FS, Sorenmo K: Recurrence rates and sites for ous mast cell tumours, Vet Res Commun 31:287–296, 2007.
grade II canine cutaneous mast cell tumors following complete sur- 103. Thompson JJ, Pearl DL, Yager JA, et al.: Canine subcutaneous
gical excision, J Am Anim Hosp Assoc 38:71–73, 2002. mast cell tumor: characterization and prognostic indices, Vet Pathol
83. Schultheiss PC, Gardiner DW, Rao S, et al.: Association of histo- 48:156–168, 2011.
logic tumor characteristics and size of surgical margins with clinical 104. Ayl RD, Couto CG, Hammer AS, et al.: Correlation of DNA
outcome after surgical removal of cutaneous mast cell tumors in ploidy to tumor histologic grade, clinical variables, and survival in
dogs, J Am Vet Med Assoc 238:1464–1469, 2011. dogs with mast cell tumors, Vet Pathol 29:386–390, 1992.
84. Hume CT, Kiupel M, Rigatti L, et al.: Outcomes of dogs with 105. Patruno R, Arpaia N, Gadaleta CD, et al.: VEGF concentration
grade 3 mast cell tumors: 43 cases (1997-2007), J Am Anim Hosp from plasma-activated platelets rich correlates with microvascu-
Assoc 47:37–44, 2011. lar density and grading in canine mast cell tumour spontaneous
85. Northrup NC, Harmon BG, Gieger TL, et al.: Variation among model, J Cell Mol Med 13:555–561, 2009.
pathologists in histologic grading of canine cutaneous mast cell 106. Strefezzi Rde F, Xavier JG, Catao-Dias JL: Morphometry of canine
tumors, J Vet Diagn Invest 17:245–248, 2005. cutaneous mast cell tumors, Vet Pathol 40:268–275, 2003.
86. Northrup NC, Howerth EW, Harmon BG, et al.: Variation among 107. Strefezzi Rde F, Xavier JG, Kleeb SR, et al.: Nuclear morphometry
pathologists in the histologic grading of canine cutaneous mast cell in cytopathology: a prognostic indicator for canine cutaneous mast
tumors with uniform use of a single grading reference, J Vet Diagn cell tumors, J Vet Diagn Invest 21:821–825, 2009.
Invest 17:561–564, 2005. 108. Webster JD, Kiupel M, Kaneene JB, et al.: The use of KIT and
87. Kiupel M, Webster JD, Bailey KL, et al.: Proposal of a 2-tier histo- tryptase expression patterns as prognostic tools for canine cutane-
logic grading system for canine cutaneous mast cell tumors to more ous mast cell tumors, Vet Pathol 41:371–377, 2004.
accurately predict biological behavior, Vet Pathol 48:147–155, 109. Bergman PJ, Craft DM, Newman SJ, et al.: Correlation of his-
2011. tologic grading of canine mast cell tumors with Ki67/PCNA/
88. Sabattini S, Scarpa F, Berlato D, et al.: Histologic grading of canine AgNOR/c-Kit scores: 38 cases (2002-2003), Vet Comp Oncol 2:
mast cell tumor: is 2 better than 3? Vet Pathol 52:70–73, 2015. 98–98, 2004.
89. Preziosi R, Sarli G, Paltrinieri M: Prognostic value of intratumoral 110. Turrel JM, Kitchell BE, Miller LM, et al.: Prognostic factors for
vessel density in cutaneous mast cell tumors of the dog, J Comp radiation treatment of mast cell tumor in 85 dogs, J Am Vet Med
Pathol 130:143–151, 2004. Assoc 193:936–940, 1988.
90. Abadie JJ, Amardeilh MA, Delverdier ME: Immunohistochemical 111. Cahalane AK, Payne S, Barber LG, et al.: Prognostic factors for
detection of proliferating cell nuclear antigen and Ki-67 in mast survival of dogs with inguinal and perineal mast cell tumors treated
cell tumors from dogs, J Am Vet Med Assoc 215:1629–1634, 1999. surgically with or without adjunctive treatment: 68 cases (1994-
91. Scase TJ, Edwards D, Miller J, et al.: Canine mast cell tumors: cor- 2002), J Am Vet Med Assoc 225:401–408, 2004.
relation of apoptosis and proliferation markers with prognosis, J Vet 112. Sfiligoi G, Rassnick KM, Scarlett JM, et al.: Outcome of dogs with
Intern Med 20:151–158, 2006. mast cell tumors in the inguinal or perineal region versus other
92. Seguin B, Besancon MF, McCallan JL, et al.: Recurrence rate, clini- cutaneous locations: 124 cases (1990-2001), J Am Vet Med Assoc
cal outcome, and cellular proliferation indices as prognostic indica- 226:1368–1374, 2005.
tors after incomplete surgical excision of cutaneous grade II mast 113. Hillman LA, Garrett LD, de Lorimier LP, et al.: Biological behav-
cell tumors: 28 dogs (1994-2002), J Vet Intern Med 20:933–940, ior of oral and perioral mast cell tumors in dogs: 44 cases (1996-
2006. 2006), J Am Vet Med Assoc 237:936–942, 2010.